Vestal Point Capital LP Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Vestal Point Capital LP raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,725,000 shares of the company's stock after buying an additional 575,000 shares during the period. Structure Therapeutics comprises 2.8% of Vestal Point Capital LP's holdings, making the stock its 11th biggest holding. Vestal Point Capital LP owned about 3.01% of Structure Therapeutics worth $46,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares in the last quarter. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after purchasing an additional 953 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Structure Therapeutics by 673.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after purchasing an additional 3,549 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Structure Therapeutics during the fourth quarter valued at approximately $113,000. 91.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company. William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, HC Wainwright dropped their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $79.86.

Structure Therapeutics Stock Up 2.1%

Shares of Structure Therapeutics stock traded up $0.50 during trading on Thursday, reaching $24.65. The company's stock had a trading volume of 558,347 shares, compared to its average volume of 932,563. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The company has a 50-day simple moving average of $21.40 and a two-hundred day simple moving average of $26.23. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -33.31 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.